Intended for healthcare professionals


British man with CJD gets experimental treatment in world first

BMJ 2018; 363 doi: (Published 31 October 2018) Cite this as: BMJ 2018;363:k4608
  1. Clare Dyer
  1. The BMJ

A High Court judge has given the go ahead for a middle aged man with sporadic Creutzfeldt-Jakob disease (CJD) to become the first human worldwide to be given the novel drug PRN100.1

The drug, a humanised monoclonal antibody, has been in development since 2007 and has been tested on animals, but researchers have been unable to raise the funds for a clinical trial.

Because of his condition the man, referred to as KG, lacks the full mental capacity to weigh up the risks and benefits of the treatment. But he, his family, the official solicitor as his representative, and University College London Hospitals NHS Foundation Trust have all …

View Full Text

Log in

Log in through your institution


* For online subscription